Table 1.
Baseline characteristics of study population.
| Characteristics | Total |
cT1-2N0 |
cT1-2N1 |
LABC |
p-value |
|---|---|---|---|---|---|
| N = 1999 | n = 457 (%) | n = 884 (%) | n = 658 (%) | ||
| Age, years | 0.658 | ||||
| <50 | 976 | 230 (50.3) | 433 (49.0) | 313 (47.6) | |
| ⩾50 | 1023 | 227 (49.7) | 451 (51.0) | 345 (52.4) | |
| Menopausal status | 0.089 | ||||
| Premenopausal | 1093 | 255 (55.8) | 501 (56.7) | 337 (51.2) | |
| Postmenopausal | 906 | 202 (44.2) | 383 (43.3) | 321 (48.8) | |
| Histology | 0.027 | ||||
| IDC | 1880 | 418 (22.2) | 840 (44.7) | 622 (33.1) | |
| Other invasive | 119 | 39 (32.8) | 44 (37.0) | 36 (30.3) | |
| Tumor grade | <0.001 | ||||
| I–II | 633 | 211 (46.2) | 281 (31.8) | 141 (21.4) | |
| III | 346 | 67 (14.7) | 144 (16.3) | 135 (20.5) | |
| NA | 1020 | 179 (39.2) | 459 (51.9) | 382 (58.1) | |
| ER | 0.223 | ||||
| Negative | 626 | 150 (32.8) | 259 (29.3) | 217 (33.0) | |
| Positive | 1373 | 307 (67.2) | 625 (70.7) | 441 (67.0) | |
| PR | 0.163 | ||||
| Negative | 807 | 184 (40.3) | 339 (38.3) | 284 (43.2) | |
| Positive | 1192 | 273 (59.7) | 545 (61.7) | 374 (56.8) | |
| HER2 | 0.409 | ||||
| Negative | 1280 | 289 (63.2) | 580 (65.6) | 411 (62.5) | |
| Positive | 719 | 168 (36.8) | 304 (34.4) | 247 (37.5) | |
| Ki-67 (%) | 0.004 | ||||
| <14 | 282 | 84 (18.4) | 114 (12.9) | 84 (12.8) | |
| ⩾14 | 1670 | 356 (77.9) | 755 (85.4) | 559 (85.0) | |
| NA | 47 | 17 (3.7) | 15 (1.7) | 15 (2.2) | |
| Molecular subtype | 0.237 | ||||
| Luminal-A like | 115 | 33 (7.2) | 49 (5.5) | 33 (5.5) | |
| Luminal-B (HER2–) | 859 | 181 (39.6) | 398 (45.0) | 280 (42.6) | |
| Luminal-B (HER2+) | 437 | 103 (22.5) | 196 (22.2) | 138 (21.0) | |
| HER2-amplified | 282 | 65 (14.2) | 108 (12.2) | 109 (16.6) | |
| TNBC | 306 | 75 (16.4) | 133 (15.0) | 98 (14.9) | |
| NAC regimen | <0.001 | ||||
| Containing A | 174 | 72 (15.8) | 70 (7.9) | 32 (4.9) | |
| Containing T | 400 | 96 (21.0) | 175 (19.8) | 129 (19.6) | |
| A+T combination | 1425 | 289 (63.2) | 639 (72.3) | 497 (75.5) | |
| Targeted therapy | 0.041 | ||||
| Yes | 480 | 91 (19.9) | 215 (24.3) | 174 (26.4) | |
| No | 1519 | 366 (80.1) | 669 (75.7) | 484 (73.6) | |
| NAC cycles | <0.001 | ||||
| 4–6 | 1284 | 311 (68.1) | 592 (67.0) | 381 (57.9) | |
| >6 | 715 | 146 (31.9) | 292 (33.0) | 277 (42.1) | |
| Breast surgery | <0.001 | ||||
| BCS | 196 | 68 (14.9) | 86 (9.7) | 42 (6.4) | |
| Mastectomy | 1803 | 389 (85.1) | 798 (90.3) | 616 (93.6) | |
| ALN surgery | <0.001 | ||||
| SLNB | 119 | 82 (17.9) | 19 (2.1) | 18 (2.7) | |
| ALND | 1880 | 375 (82.1) | 865 (97.9) | 640 (97.3) |
A, anthracyclines; ALN, axillary lymph node; ALND, axillary lymph node dissection; BCS, breast conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; LABC, locally advanced breast cancer; NA, not available; NAC, neoadjuvant chemotherapy; PR, progesterone receptor; SLNB, sentinel lymph node biopsy; T, taxanes; TNBC, triple negative breast cancer.